positive crohns tx study, 1994

January 22, 2006

With the inclusion of nitroimidazoles, one might do even better than

whats seen in this trial. I have read some old case reports on great

results from nitroimidazoles in Crohns. I found this while checking

to see if the new Gibson P et al abx trial for Crohns was out yet,

which it isnt.

============================

Am J Gastroenterol. 1994 Apr;89(4):513-8. Related Articles, Links

Antimycobacterial therapy in Crohn's disease: results of a

controlled, double-blind trial with a multiple antibiotic regimen.

Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C.

Department of Gastroenterology, Ospedale Nuovo Regina Margherita,

Rome, Italy.

Several recent reports have suggested an association of atypical

mycobacteria with Crohn's disease. OBJECTIVES: The goal of this

double-blind, placebo-controlled trial was to determine the efficacy

of treatment with antimycobacterial drugs in maintaining clinical

remission and in reducing active inflammatory lesions. METHODS: Forty

patients (15 male) with refractory, steroid-dependent Crohn's disease

were randomized to receive 2 months of tapering steroids plus either

a 9-month regimen of ethambutol, clofazimine, dapsone and 1-day dose

only of rifampicin (n = 22), or identical placebo. RESULTS: Three

patients (two on active drug) were unable to discontinue steroids,

and one patient on active drug was withdrawn for side effects during

the first 2 months. Three of the remaining 19 patients on active drug

relapsed during the study period, compared with 11 of 17 on placebo

(log likelihood ratio = 4.6; p = 0.03). Another patient was withdrawn

in remission at 5 months for anemia related to dapsone. Nine patients

whose disease relapsed or persisted on placebo were crossed over to

active drug; five achieved sustained remission, two failed, and two

were withdrawn for side effects. Substantial endoscopic or radiologic

healing did not occur. CONCLUSION: This study suggests that the

treatment regimen with rifampicin, ethambutol, clofazimine, and

dapsone is effective in relief of symptoms and maintenance of

remission in some Crohn's disease patients.

Publication Types:

Clinical Trial

Randomized Controlled Trial

PMID: 8147352 [PubMed - indexed for MEDLINE]

Recommended Posts